KNSA
Kiniksa Pharmaceuticals Ltd
76.30$
+0.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +24.4% | -4.2% | +36.0% | +3.3% | +9.2% | +12.4% | +13.8% | +15.3% | +11.8% | +6.0% | +13.7% | – | |
| – | -2.3% | +17.9% | +34.6% | +16.4% | +33.9% | -6.8% | +15.2% | +17.7% | +9.0% | +5.8% | +15.8% | – | |
| – | +42.8% | -14.7% | +37.0% | -5.1% | -10.2% | +35.1% | +12.7% | +13.4% | +14.2% | +6.2% | +11.9% | – | |
| – | +17.9% | +32.1% | -8.7% | +9.0% | +34.8% | -45.0% | -3.0% | +28.7% | +43.5% | -20.7% | +48.9% | – | |
| – | +6.6% | +5.3% | +9.6% | +9.4% | -12.6% | +7.4% | +7.7% | +4.8% | +15.6% | +7.7% | +4.4% | – | |
| – | +11.8% | +14.7% | +2.2% | +9.3% | +4.4% | -16.9% | +4.4% | +11.6% | +24.6% | -2.9% | +18.2% | – | |
| – | – | -20,522.2% | – | – | – | – | +51.9% | +19.2% | -17.7% | +48.1% | -7.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -682.7% | – | -412.5% | – | – | +47.0% | +18.7% | -14.3% | +40.4% | -4.7% | – | |
| – | -525.4% | – | +81.2% | -11.6% | -247.3% | – | -28.2% | +72.9% | +4.0% | +11.2% | -43.4% | – | |
| – | – | -170.2% | – | – | – | – | +108.8% | +3.4% | -23.0% | +59.1% | +12.6% | – | |
| – | – | -614.1% | – | -348.8% | – | – | +46.0% | +18.5% | -13.8% | +39.7% | -16.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.